Lessons learned from CMS's National Partnership to Improve Dementia Care: a thematic synthesis of multiple stakeholder-engaged studies.
National Partnership
antipsychotic
dementia
nursing home
Journal
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society
ISSN: 1479-8301
Titre abrégé: Psychogeriatrics
Pays: England
ID NLM: 101230058
Informations de publication
Date de publication:
24 Jun 2024
24 Jun 2024
Historique:
revised:
07
06
2024
received:
04
03
2024
accepted:
11
06
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
aheadofprint
Résumé
Antipsychotic prescribing in United States nursing homes (NHs) has decreased since the Center for Medicare & Medicaid Service debuted the National Partnership to Improve Dementia Care in Nursing Homes (NP); however, reductions have stalled. To help explain persistent antipsychotic use despite the NP's reduction efforts, the perspectives of diverse NP stakeholders were qualitatively assessed. This study aimed to re-evaluate these individual perspectives in combined thematic synthesis to discover NP improvement opportunities undetectable in single stakeholder assessments. Thematic synthesis. Through immersive crystallisation, original source coding results were organised into related descriptive themes. Similarities and differences were identified, and descriptive themes were regrouped into new, increasingly abstract, analytical themes. This cycle continued until variances were resolved and analytic themes sufficiently described and explained all initial descriptive themes. Three analytic themes emerged regarding NP improvement opportunities. The NP's positive impacts would be augmented by: (i) a deeper and expanded appreciation of stakeholder perspectives; (ii) more urgent and rapid adaptation to unintended adverse outcomes; and (iii) greater recognition of the contextual and environmental factors influencing decisions to prescribe or not prescribe antipsychotic medications. Stakeholder groups described: perspectives they perceived as inadequately considered by the NP; insufficient NP engagement with the stakeholders capable of creating evidenced, affordable, and available non-pharmacologic therapies for dementia symptoms; recognition that dementia interventions effective for a specific individual at a specific time in a specific community may not generalise; and diverse ongoing undesirable outcomes from NP policies that could be mitigated by NP modifications. The NP has done much to advance dementia care in NHs. Notwithstanding, these results suggest the NP would only be improved through increasingly comprehensive inclusion of stakeholder perspectives, enhanced incorporation of individual contextual factors, and a more decisive mechanism for ongoing and continual adaptation.
Sections du résumé
BACKGROUND
BACKGROUND
Antipsychotic prescribing in United States nursing homes (NHs) has decreased since the Center for Medicare & Medicaid Service debuted the National Partnership to Improve Dementia Care in Nursing Homes (NP); however, reductions have stalled. To help explain persistent antipsychotic use despite the NP's reduction efforts, the perspectives of diverse NP stakeholders were qualitatively assessed. This study aimed to re-evaluate these individual perspectives in combined thematic synthesis to discover NP improvement opportunities undetectable in single stakeholder assessments.
METHODS
METHODS
Thematic synthesis. Through immersive crystallisation, original source coding results were organised into related descriptive themes. Similarities and differences were identified, and descriptive themes were regrouped into new, increasingly abstract, analytical themes. This cycle continued until variances were resolved and analytic themes sufficiently described and explained all initial descriptive themes.
RESULTS
RESULTS
Three analytic themes emerged regarding NP improvement opportunities. The NP's positive impacts would be augmented by: (i) a deeper and expanded appreciation of stakeholder perspectives; (ii) more urgent and rapid adaptation to unintended adverse outcomes; and (iii) greater recognition of the contextual and environmental factors influencing decisions to prescribe or not prescribe antipsychotic medications. Stakeholder groups described: perspectives they perceived as inadequately considered by the NP; insufficient NP engagement with the stakeholders capable of creating evidenced, affordable, and available non-pharmacologic therapies for dementia symptoms; recognition that dementia interventions effective for a specific individual at a specific time in a specific community may not generalise; and diverse ongoing undesirable outcomes from NP policies that could be mitigated by NP modifications.
CONCLUSIONS
CONCLUSIONS
The NP has done much to advance dementia care in NHs. Notwithstanding, these results suggest the NP would only be improved through increasingly comprehensive inclusion of stakeholder perspectives, enhanced incorporation of individual contextual factors, and a more decisive mechanism for ongoing and continual adaptation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Japanese Psychogeriatric Society.
Références
National Partnership to Improve Dementia Care in Nursing Homes. Antipsychotic Medication Use Data Report (April 2022), 2022. Available from: https://www.cms.gov/files/document/antipsychotic-medication-use-data-report-2021q4-updated-07292022.pdf.
CMS Announces National Partnership to Improve Dementia Care in Nursing Homes, 2012. Available from: https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press‐Releases/2012‐Press‐Releases‐Items/2012‐05‐30.html.
FDA NEWS RELEASE. FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs 2008, 2008. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116912.htm.
Winter JD, Kerns JW, Winter KM, Etz R. Public quality reporting and nursing home admission decisions. J Am Med Dir Assoc 2022; 23: 2035–2037.
Kerns JW, Winter JD, Winter KM, Boyd T, Etz RS. Primary care physician perspectives about antipsychotics and other medications for symptoms of dementia. J Am Board Fam Med 2018; 31: 9–21.
Kerns JW, Winter JD, Winter KM, Kerns CC, Etz RS. Caregiver perspectives about using antipsychotics and other medications for symptoms of dementia. Gerontologist 2018; 58: e35–e45.
Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol 2008; 8: 45.
Crabtree BF, Miller WL. Doing Qualitative Research, 3rd edn. Thousand Oaks, CA: Sage Publications, 2022; 456.
U.S. Department of Health and Human Services Office of Inspector General: Long‐Term Trends of Psychotropic Drug Use in Nursing Homes, 2022. Available from: https://oig.hhs.gov/oei/reports/OEI-07-20-00500.pdf.
Interim report on the CMS Nationial Partnership to Improve Dementia Care in Nursing Homes. Q4 2011‐Q1 2014, 2014. Available from: https://www.cms.gov/Medicare/Provider‐Enrollment‐and‐Certification/SurveyCertificationGenInfo/Downloads/Survey‐and‐Cert‐Letter‐14‐19.pdf.
Heckert A, Forsythe LP, Carman KL et al. Researchers, patients, and other stakeholders' perspectives on challenges to and strategies for engagement. Res Involv Engagem 2020; 6: 60.
Ellis LE, Kass NE. How are PCORI‐funded researchers engaging patients in research and what are the ethical implications? AJOB Empir Bioeth 2017; 8: 1–10.
Witteman HO, Chipenda Dansokho S, Colquhoun H et al. Twelve lessons learned for effective research partnerships between patients, caregivers, clinicians, academic researchers, and other stakeholders. J Gen Intern Med 2018; 33: 558–562.
The National Imperative to Improve Nursing Home Quality. Honoring Our Commitment to Residents, Families, and Staff, 2022; Available from: https://www.ncbi.nlm.nih.gov/pubmed/36198022.
Winter JD, Kerns JW, Winter KM, Richards A, Sabo R. Long‐stay mood stabilizer use increasing as prescription of antipsychotics decreases. GeroPsych J Gerontopsychol Geriatr Psychiatry 2023; 36: 42–47.
Gerlach LB, Kales HC, Kim HM et al. Trends in antipsychotic and mood stabilizer prescribing in long‐term Care in the U.S.: 2011‐2014. J Am Med Dir Assoc 2020; 21: 1629–1635.e8.
Winter JD, Kerns JW, Winter KM, Richards A, Sabo RT. Unreported antipsychotic use increasing in nursing homes: the impact of quality‐measure exclusions on the percentage of long‐stay residents who got an antipsychotic medication quality‐measure. Am J Geriatr Psychiatry 2021; 29: 704–708.
Winter JD, Kerns JW, Winter KM, Sabo RT. Increased reporting of exclusionary diagnoses inflate apparent reductions in long‐stay antipsychotic prescribing. Clin Gerontol 2019; 42: 297–301.
OIG Draft Report: CMS Could Improve the Data It Uses to Monitor Antipsychotic Drugs in Nursing Homes, 2021. Available from: https://oig.hhs.gov/oei/reports/OEI‐07‐19‐00490.pdf.
Adjusting Quality Measure Ratings Based on Erroneous Schizophrenia Coding, and Posting Citations Under Dispute, 2023. Available from: https://www.cms.gov/files/document/qso‐23‐05‐nh‐adjusting‐quality‐measure‐ratings‐based‐erroneous‐schizophrenia‐coding‐and‐posting.pdf.
Updates to Nursing Home Care Compare Staffing and Quality Measures, 2023. Available from: https://www.cms.gov/files/document/qso-23-21-nh.pdf.
Jacobs DB, Schreiber M, Seshamani M. The CMS strategy to promote equity in quality and value programs. JAMA Health Forum 2023; 4: e233557.
Doyle LH. Synthesis through meta‐ethnography: paradoxes, enhancements, and possibilities. Qual Res 2003; 3: 321–344.
Shireman TI, Fashaw‐Walters S, Zhang T et al. Federal Nursing Home Policies on antipsychotics had similar impacts by race and ethnicity for residents with dementia. J Am Med Dir Assoc 2023; 24: 1283–1289.e4.
Rantz M, Ersek M. Care delivery, quality measurement, and quality improvement in nursing homes: issues and recommendations from the National Academies' report on the quality of Care in Nursing Homes. J Am Geriatr Soc 2023; 71: 329–334.